Alnylam submits supplemental new drug application (snda) to u.s. food and drug administration (fda) for onpattro® (patisiran) for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--( business wire )--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the submission of its supplemental new drug application (snda) to the u.s. food and drug administration (fda) for patisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis with cardiomyopathy. patisiran is the established name for onpattro®, which is currently approved by the u.s. fda for the treatment of the polyneuropathy of hereditary attr amyloidosis in adults.
ALNY Ratings Summary
ALNY Quant Ranking